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Abstract
Background: A dose–response relationship between the amount of inflamed
periodontal tissue and HbA1c level, might be indicative for a causal association
between periodontitis and type 2 diabetes.
Aim: To assess a dose–response relationship between the periodontal inflamed
surface area (PISA), as a measure of the amount of inflamed periodontal tissue, and
HbA1c levels in type 2 diabetics.
Material and Methods: Forty consecutive dentate type 2 diabetics attending their
general practitioner for regular check-up, underwent full-mouth probing pocket depth
and bleeding on probing assessment. From these data PISA was calculated. HbA1c
levels were retrieved from patients’ medical files. The dose–response relationship
between PISA and HbA1c levels was assessed using multiple linear regression
analyses, controlling for factors that might influence PISA or HbA1c levels.
Results: The higher the PISA of type 2 diabetics was, the higher their HbA1c levels
were. On a group level, an increase of PISA with 333 mm2 was associated with a 1.0
percentage point increase of HbA1c, independent of the influence of other factors.
Conclusion: On a group level, there is a dose–response relationship between PISA
and HbA1c in type 2 diabetics. This might be an indication of a causal relationship
between type 2 diabetes and periodontitis.
Key words: glycosylated hemoglobin A;
periodontal inflamed surface area (PISA);
periodontitis; type 2 diabetes mellitus
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It was estimated that 194 million people
suffered from diabetes mellitus across
the globe in 2003, equalling 5.1% of
the world’s population. This is esti-
mated to increase to 333 million, or
6.3% of the world’s population, in the
year 2025 (International Diabetes Fed-
eration 2003). Type 2 diabetes mellitus
is the most prevalent type of the
disease, occurring in 90–95% of all
diabetic patients (Taylor 2001). Type 2
diabetes mellitus is characterized by
insulin resistance, insensitivity to the
effects of insulin, which results in
elevated levels of blood glucose. As
a consequence of prolonged elevated
blood–glucose levels (poor glycaemic
control), blood vessels sustain damage
resulting in complications commonly
associated with diabetes, namely:
atherosclerosis, myocardial infarction,
retinopathy, nephropathy, neuropathy,
delayed wound healing and an increased
risk of infections (International Diabetes
Federation 2003).
Inflammation has been postulated as
an important factor initiating the onset
of type 2 diabetes mellitus (Pradhan
et al. 2001, Hu et al. 2004). Further-
more, inflammation has been shown to
exert a negative effect on glycaemic
control in diabetics (Schmidt et al.
1999, Pradhan et al. 2001, Pradhan &
Ridker 2002). When inflammatory med-
iators as tumour necrosis factor-a (TNF-
a), interleukin (IL)-6 and IL-1 enter the
systemic circulation, they alter lipid and
glucose metabolism (Iacopino & Cutler
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2000), and induce insulin resistance
(Grunfeld et al. 1990, Feingold & Grun-
feld 1992, Pickup et al. 1997). Because
periodontitis poses an inflammatory bur-
den with, among others, TNF-a, IL-6
and IL-1 entering the systemic circula-
tion (Grossi & Genco 1998, Engebret-
son et al. 2007), periodontitis may
induce insulin resistance. In accordance,
it has been shown that periodontitis has
a negative effect on glycaemic control
(Taylor et al. 1996, Collin et al. 1998,
Saito et al. 2004). Moreover, diabetics
with severe periodontitis had more
diabetic complications than diabetics
with mild or no periodontitis (Finestone
& Boorujy 1967, Thorstensson et al.
1996). Finally, treatment of perio-
dontitis has been shown to improve
glycaemic control in type 2 diabetics
(Grossi et al. 1997, Iwamoto et al. 2001,
Stewart et al. 2001, Rodrigues et al.
2003, Kiran et al. 2005, Faria-Almeida
et al. 2006, Navarro-Sanchez et al. 2007,
O’Connell et al. 2008).
While periodontitis may be a risk
factor for development or deterioration
of type 2 diabetes, type 2 diabetes may
also be a risk factor for the development
of periodontitis. Patients with type 2
diabetes suffer from periodontitis more
often and more severely than non-dia-
betics (Emrich et al. 1991, Collin et al.
1998, Tsai et al. 2002, Campus et al.
2005, De Silva et al. 2006, Struch et al.
2008). Hence, there may be a bilateral
causal relationship between perio-
dontitis and type 2 diabetes, with one
influencing the other and vice versa.
Establishing the potentially causal
nature of the association between perio-
dontitis and diabetes requires assessing
dose–response relationships between the
inflammatory burden posed by perio-
dontitis and glycaemic control. A pro-
blem that needs to be resolved is that, in
contrast to glycaemic control (com-
monly assessed by measuring the per-
centage of haemoglobin that is glycated,
HbA1c level), there is as yet no common
way to assess the inflammatory burden
posed by periodontitis.
The inflammatory burden, consisting
of bacteria and inflammatory mediators
entering the systemic circulation, is
thought to be related to the amount of
inflamed periodontal tissue. The greater
the amount of inflamed periodontal tis-
sue is, the greater the amount, and the
chance of, bacteria and inflammatory
mediators entering the systemic circula-
tion may be thought to be. Therefore,
classifying periodontitis as a risk factor
for other diseases should be done by a
measure that quantifies the amount of
inflamed periodontal tissue. Classifica-
tions of periodontitis that are currently
used, take mean probing pocket depth
(PPD), mean clinical attachment level
(CAL) or a particular cut-off point for
PPD or CAL as a means to classify or
define periodontitis. Neither PPD nor
CAL are appropriate to assess dose–
response relationships between perio-
dontitis and HbA1c, because PPD and
CAL are linear measures that do not
quantify the amount of inflamed perio-
dontal tissue. Therefore, a new measure
of periodontitis as a risk factor for other
diseases was developed, the periodontal
inflamed surface area (PISA) (Nesse
et al. 2008).
PISA reflects the surface area of
bleeding pocket epithelium in square
millimetres. Because PISA quantifies
the amount of inflamed periodontal tis-
sue, it is assumed that PISA quantifies
the inflammatory burden posed by
periodontitis. The aim of this study
was to assess a dose–response relation-




This study was performed on Curacao,
an island that is part of the Netherlands
Antilles. During a 3-month period, from
September 2006 until November 2006,
dentate type 2 diabetics who came for
regular check-ups to their general prac-
titioner were asked to participate in this
study. The following inclusion criteria
were used:
(1) Availability of at least 1 measure-
ment of HbA1c level in the past 3
months,
(2) Having at least eight remaining
teeth,
(3) Not having used antibiotics in the
past 3 months,
(4) Not having received periodontal
treatment in the past 6 months.
Because no data regarding the asso-
ciation between PISA and HbA1c exists,
no formal sample size calculation could
be performed. Therefore a convenience
sample was taken. During the inclusion
period, a total of 40 diabetic patients
met the inclusion criteria. All agreed to
participate in this study. All participants
signed an informed consent agreement.
All patients agreed to (1) disclose
data in their medical file for research
purposes, (2) complete a questionnaire
[assessing socio-economic status (SES),
length and weight, smoking and oral
hygiene practises], and (3) undergo a
full-mouth PPD assessment. From the
medical files, data regarding HbA1c
levels, number of years since diagnosed
with type 2 diabetes mellitus, and the
usage of medication were retrieved.
Materials and Methods
On the basis of education, income and
profession, patients were categorized into
low, middle and high SES. Length and
weight were used to calculate body mass
index (BMI): weight in kilograms divided
by the square of height in metres. Patients
were categorized into four BMI classes
according to WHO classifications; under-
weight (BMI418.5 kg/m2), healthy
weight (BMI 18.5–o25 kg/m2), over-
weight (BMI 25–o30 kg/m2) and obesity
(BMIX30 kg/m2) (WHO 1995, 2000).
Full-mouth PPD and bleeding on
probing (BOP) data on six sites per
tooth were obtained using a pocket
probe (PCP106, Hu-Friedys, Chicago,
IL, USA). Oral hygiene was assessed
using Silness and Lo¨e’s plaque index
(Loe 1967). All patients were investi-
gated by one researcher (A. L.), then
bachelor of dental surgery, who was
trained during a course in clinical perio-
dontology. Data on PPD and BOP on six
sites per tooth were entered in a spread-
sheet to calculate the PISA for each
patient (Nesse et al. 2008). This spread-
sheet can be accessed via http://
www.parsprototo.info/docs/PISA_CAL.
xls and is free for use. PISA was calcu-
lated with this spreadsheet in four steps:
(1) After filling in PPD measurements
at six sites per tooth, the computer
calculates the mean PPD for each
particular tooth.
(2) The mean PPD around a particular
tooth is entered into formula that
translate this linear mean PPD into
the periodontal epithelial surface
area (PESA) for that specific tooth
(Hujoel et al. 2001). The PESA for a
particular tooth is the root surface
area of that tooth (in mm2) that is
covered with pocket epithelium.
(3) The PESA may consist of un-
inflamed pocket epithelium that
does not pose an inflammatory
burden. Therefore, the PESA for a
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particular tooth is subsequently
multiplied by the proportion of sites
around that tooth that was affected
by BOP. If, for example, three out
of the maximum of six sites were
affected by BOP, the PESA of that
particular tooth was multiplied by 3/
6, thereby rendering the Periodontal
Inflamed Surface Area (PISA) for
that specific tooth.
(4) The sum of PISA’s around each
individual tooth is calculated,
amounting to the total PISA within
a patient’s mouth.
Please read the discussion section of
this paper and the article entitled
‘‘PISA, quantifying inflammatory bur-
den’’ in an earlier version of this journal
(Nesse et al. 2008) for a more detailed
explanation of PISA and its calculation.
Statistical analysis
To analyse dose–response relationships
between PISA and HbA1c levels, multi-
ple linear regression analyses were per-
formed. The outcome variable was
HbA1c and as potential predictors
PISA, sex, oral hygiene (high versus
low/middle), smoking (yes versus no),
and (SES; high/middle versus low),
BMI and ‘‘the number of years since
diagnosed with diabetes’’ were entered
in the regression equation (method;
stepwise backward). The significance
of the contribution of the variables to
the model was estimated and compared
with the removal criterion (p5 0.1).
When a potential predictor met the
removal criterion, it was removed from
the regression model. The model was
then re-estimated for the remaining pre-
dictor variables, and the process was
repeated until no further predictors met
the removal criterion. The residuals of
the last model were checked for normal-
ity. Residuals were standardized and
analyzed. Statistics were calculated
using SPSS 14.0.
Results
Patients’ characteristics are summed up
in Table 1. Our study population con-
sisted of mainly female type 2 diabetics
(83%). Only four (10%) out of the 40
included patients had a healthy weight,
90% was either overweight (n5 11,
27%) or obese (n5 25, 63%). HbA1c
ranged from 4.9% to 14.2%, with 60%
of the study population (n5 24) having
an HbA1c level above the recommended
7.0%. The PISA ranged from 0 to
1087 mm2, median of 151 mm2, with
an inter-quartile range of 39–307 mm2.
Only two patients smoked.
In the multiple linear regression ana-
lysis it appeared that PISA (b5 0.003,
95% CI5 0.001–0.005) was the only
predictor significantly associated with
HbA1c level, r25 17.5% (Table 2;
model A). However, when plotting
standardized residuals we found one
extreme outlier (Fig. 1). For that case
there was a large difference between the
observed and predicted value of HbA1c.
The outlier was deleted and the regres-
sion analysis was repeated (Table 2;
model B), after which residuals were
normally distributed.
The results indicate that on a group
level, an increase in PISA of 1 mm2 is
associated with a rise in HbA1c of
0.003% (Table 2, Fig. 1). This means
that on a group level, an increase of
PISA of 333 mm2 is associated with an
increase in HbA1c of 1.0 percentage
point.
Discussion
This study shows that a dose–response
relationship exists between control of
blood–glucose levels over time
(HbA1c) and the amount of inflamed
periodontal tissue (PISA) in type 2
diabetics. Namely, on a group level, an
Table 1. Patients’ characteristics
Sex: % (numbers) 83% (33) female and 17% (7) male
Age: mean ( SD) 58 ( 9.5) years
Diagnosed with DM 2: median (IQR) 7.0 (2.3–12.0) years
BMI: mean ( SD) 31.1 ( 4.6) kg/m2
WHO BMI classification: % (numbers)
Healthy: BMI 18.5 to o25 kg/m2 10% (4)
Overweight: BMI 25 to o30 kg/m2 27% (11)
Obese: BMIX30 kg/m2 63% (25)












PISA: median (IQR) 151 (39–307) mm2
HbA1c: mean ( SD) 7.7 ( 1.8)%
PISA, periodontal inflamed surface area; SD, standard deviation; IQR, inter quartile range; DM 2,
type 2 diabetes mellitus; BMI, body mass index; WHO, World Health Organisation; SES, socio-
economic status.
Table 2. Results from multiple linear regression analyses (models to predict HbA1c)
Model and predictors b p-value of b r2 95% confidence
interval of b
Model A
Constant 7.017 o0.001 0.175 6.289–7.744
PISA 0.003 0.001 0.001–0.005
Model B
Constant 6.874 o0.001 0.367 6.107–7.641
PISA 0.003 o0.001 0.002–0.005
SES high/middle  1.055 0.012  1.866 to  0.244
Years diagnosed with DM 2 0.048 0.093  0.008 to 0.104
Model A is the resulting model from the regression analysis of all patients.
Model B is the resulting model from the regression analysis excluding one extreme outlier.
Dependent variable: HbA1c(%); independent variables initially entered into the model: sex, oral
hygiene, body mass index; PISA, periodontal inflamed surface area; SES, socio-economic status,
years since diagnosed with type 2 diabetes mellitus (DM 2).
p, probability; a p-value of 40.05 was considered statistically significant; b, unstandardized
coefficient.
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increase in PISA of 333 mm2 is asso-
ciated with an increase of HbA1c with
1.0% (Fig. 1, Table 2, model A). Simi-
larly a decrease in PISA of 333 mm2 is
associated with a decrease of HbA1c
with 1.0%. This dose–response relation-
ship appeared to be independent of
factors as sex, oral hygiene, SES, BMI,
smoking and the number of years since
diagnosed with type 2 diabetes mellitus,
when all patients were included in the
analysis.
When the analysis was repeated with-
out the outlier with the unusually high
standard residual, the b for PISA was
basically unchanged (Table 2, model B).
However, SES and number of years
since diagnosed with type 2 diabetes
mellitus were added as predictors of
HbA1c. The explained variance increa-
sed from 17.5% (model A) to 36.7%
(model B). Model B appeared to
strengthen the notion of an association
between PISA and HbA1c, because the
lower bound of the 95% confidence
interval went up from 0.001 (model A)
to 0.002 (model B).
Although a decrease of Hb1Ac with
1.0 percentage point seems to be minor
at a first glance, it should be noted that a
decrease of HbA1c with 1.0 percentage
point is associated with a 25% reduction
of the risk of dying from cardiovascular
diseases (Balady et al. 2007). Because
treatment of periodontitis has been
shown to improve glycaemic control in
type 2 diabetics (Grossi et al. 1997,
Iwamoto et al. 2001, Stewart et al.
2001, Rodrigues et al. 2003, Kiran et
al. 2005, Faria-Almeida et al. 2006,
Navarro-Sanchez et al. 2007, O’Connell
et al. 2008) the potential benefit of
reducing the PISA, in case of a causal
association between PISA and HbA1c,
might be high. For example, 25% of our
population has a PISA above 300 mm2.
Reducing these patients’ PISA might
reduce HbA1c by up to 1 percentage
point, thereby potentially reducing their
risk of dying from cardiovascular dis-
eases by up to 25% (Balady et al. 2007).
However, because the effect of perio-
dontal treatment on diabetic control and
systemic inflammation are not proven
beyond doubt, there is a need to perform
large well-designed randomized con-
trolled clinical trials to establish the
benefit of periodontal treatment to gly-
caemic control in type 2 diabetics
(Kinane & Bouchard 2008). These stu-
dies could simultaneously elucidate the
potential causal nature of the association
between periodontitis and glycaemic
control.
Type 2 diabetics suffer from perio-
dontitis more often and more severely
than non-diabetics (Emrich et al. 1991,
Collin et al. 1998, Tsai et al. 2002,
Campus et al. 2005, De Silva et al.
2006, Struch et al. 2008). The dose–
response relationship between PISA and
HbA1c may also be explained in this
light, i.e. type 2 diabetics with poor
glycaemic control (high HbA1c) might
be more likely to develop severe perio-
dontitis (high PISA). Whether perio-
dontitis deteriorates glycaemic control
or diabetes causes periodontitis, mea-
sures that safeguard periodontal health
may need to become part of regular care
of patients with poorly controlled type 2
diabetes, if it is proven that HbA1c is
indeed causally related to PISA.
Recently it was posed that PISA pre-
dicts the probability of periodontitis to
cause or deteriorate other diseases by
quantifying the inflammatory burden
posed by periodontitis (Nesse et al.
2008). This study revealed that PISA
indeed appears to be a valuable tool to
assess dose–response relationships
between the amount of inflamed perio-
dontal tissue and a well-defined disease
activity parameter as HbA1c. However,
further studies are needed to confirm
that PISA quantifies the inflammatory
burden posed by periodontitis. This
could be done by assessing dose–
response relationships between PISA
and blood levels of inflammatory med-
iators as TNF-a, IL-6 and IL-1.
A limitation of this study is the
relatively low sample size of 40 type 2
diabetics. Reservations should be held
about generalizing results from studies
with a small sample size. Another lim-
itation that could hinder generalization
of our results, is that all patients
included in this study were of mixed
black origin living in the Netherlands
Antilles, 90% of the study population
was either overweight or obese, and
83% was female. Ethnicity may be an
effect modifier in the relationship
between PISA and HbA1c, as could
BMI and sex (although we controlled
for the effects the latter two). In other
words, obese women of mixed black
origin from the Netherlands Antilles
might have a different dose–response
relationship between PISA and HbA1c
than male patients of different weight
and ethnic origin. Regardless of the
existence of effect modification, this
study shows a clear dose–response rela-
tionship between PISA and HbA1c.
Although this dose–response relation-
ship may differ depending on the pre-
sence of effect modifiers, given the large
number of studies showing an associa-
tion between diabetes and periodontitis
across different populations, the dose–
response relationship might be present
in other populations as well.
It should be noted that the original
PISA calculation using the online
spreadsheet (http://www.parsprototo.in-
fo/docs/PISA_CAL.xls) requires CAL
and recession measurements to be filled
in. Given the absence of data on reces-
sion measurements, for this study, we
were forced to enter PPD measurements
into the spreadsheet as CAL and enter
recession measurements into the spread-
sheet as zero. Using PPD instead of
CAL measurements, i.e. ignoring the
presence of recessions, may lead to a
slight overestimation of true PISA
(Nesse et al. 2008). However, this
underestimation is likely small and can
most probably be neglected. Moreover,
the underestimation applies to the study














r  linear Model A: 0.175 
r  linear Model B*: 0.367 
*excluding the outlier 
Fig. 1. Dose–response relationship between periodontal inflamed surface area and HbA1c.
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effects the dose–response relationship
between PISA and HbA1c levels cur-
rently observed.
In conclusion this study shows that
there is a dose–response relationship
between HbA1c levels and PISA, in
type 2 diabetics. Namely, on a group
level, an increase in PISA with 333 mm2
is associated with an increase of HbA1c
with 1.0 percentage point. This dose–
response relationship might be an indi-
cation of a causal relationship between
PISA and HbA1c. Additional studies are
needed to confirm that there is indeed a
causal nature underlying the observed
association between PISA and HbA1c.
Furthermore, this study suggests that
PISA is a useful tool to assess dose–
response relationships between the
amount of inflamed periodontal tissue
and HbA1c. However, studies still have
to confirm that PISA does indeed quan-
tify the inflammatory burden posed by
periodontitis.
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Scientific rationale for the study: To
find an indication of a causal
relationship between periodontitis
and type 2 diabetes, the associa-
tion between the amount of inflamed
periodontal tissue (PISA) and
glycaemic control (HbA1c) was
assessed.
Principal findings: The larger the
PISA of type 2 diabetics was, the
higher HbA1c levels were. On a
group level, a 333 mm2 increase of
PISA was associated with a 1.0 per-
centage point increase of HbA1c.
Practical implications: Periodontitis
might contribute to poor glycaemic
control. Poor glycaemic control
might increase periodontitis severity.
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